Aspen's generic Ozempic rival approved in South Africa, with no price or launch date yet

Aspen Pharmacare said on 11 November 2026 that it had received regulatory approval in South Africa and Brazil for its generic injectable semaglutide, the active ingredient in Novo Nordisk's Ozempic. The company has not given a launch date or price for South Africa.

By Content Staff · Published 16 November 2026

What Aspen announced

South African drugmaker Aspen Pharmacare said on Wednesday, 11 November 2026, that regulators in South Africa and Brazil had approved its generic injectable semaglutide, according to Reuters. Semaglutide is the active ingredient in Novo Nordisk's Ozempic, used for type 2 diabetes, and Wegovy, a weight-loss treatment.

The approvals follow a Canadian approval in July, according to Business Day, which also reported that Aspen had previously said it was seeking registration in about 20 more countries. In a regulatory announcement quoted by Business Insider Africa, the company said commercialisation was expected to begin in Canada, Brazil and South Africa over the next few months.

Aspen has not given specific launch dates, has not disclosed what it will charge in any of the three countries, and has not announced the brand name under which the product will be sold in South Africa or Brazil, Business Insider Africa reported.

What the product is approved for

According to Business Day, Aspen's generic semaglutide has been registered for treating adults with type 2 diabetes. Business Insider Africa described the approval as covering use alongside diet and exercise to improve blood-sugar control in adults living with the condition, and noted that the approval should not be read as permission to market the product specifically for weight loss.

Business Day reported that doctors may prescribe it "off label" for weight management. Whether any semaglutide medicine is suitable for a particular person is a decision for a doctor; readers with questions should speak to a doctor or pharmacist. See the medical disclaimer for more.

Business Insider Africa also pointed out that the approval does not allow Aspen to use the Ozempic or Wegovy names, which remain Novo Nordisk trademarks.

Pricing and manufacturing

Aspen's chief financial officer, Sean Capazario, declined to give details of the pricing strategy, Business Day reported, saying only that prices would be below those of Novo Nordisk's previously patent-protected Ozempic and Wegovy. He said Aspen expected a "crowded" field of competitors, but that lower prices were expected to grow the overall market.

Business Day reported that the product will initially be manufactured in India, with production later moving to Aspen's sterile facilities in South Africa and France. According to Reuters, Aspen is sourcing the active pharmaceutical ingredient from third-party suppliers, including India's Dr Reddy's Laboratories for the Canadian market. Business Insider Africa reported that Aspen has not said whether Dr Reddy's will also supply the ingredient for Brazil and South Africa.

Current prices for Novo Nordisk's pens are listed on the Ozempic and Wegovy prices page.

A growing field of semaglutide medicines

Aspen joins other semaglutide products already registered with SAHPRA, including Ozempic, Extensior (an authorised copy of Ozempic), Wegovy, Rybelsus tablets and Semagard, a Ranbaxy generic of Ozempic. Business Day reported that the regulator approved Semagard in July and a Novo Nordisk version branded Semditu in October, according to a database on its website, and that SAHPRA said in July it was considering 12 registration applications for generic semaglutide.

According to Aspen figures cited by Reuters, South African sales of GLP-1 medicines have grown to nearly R3 billion, with Eli Lilly's Mounjaro accounting for more than half. Aspen distributes Mounjaro in sub-Saharan Africa for Lilly. Business Day reported that Capazario did not expect sales of the generic semaglutide to cannibalise those of Mounjaro, which contains tirzepatide rather than semaglutide.

Readers comparing where to fill a semaglutide prescription can see the registered pharmacy rating.

Sources

  1. Aspen Pharmacare wins approval for generic semaglutide in Brazil, South Africa (opens in new tab) reuters.com
  2. Aspen gets regulatory nod in Brazil and SA for generic semaglutide (opens in new tab) businessday.co.za
  3. After Ozempic patent expiry, Africa’s biggest drugmaker wins Brazil approval and prepares to enter South Africa’s $182 million GLP-1 race with generic semaglutide (opens in new tab) africa.businessinsider.com

Frequently asked questions

Is there a generic Ozempic in South Africa?

Several semaglutide products are registered with SAHPRA, including Semagard, a Ranbaxy generic of Ozempic, and Extensior, an authorised copy. Aspen Pharmacare said on 11 November 2026 that its generic injectable semaglutide had also been approved in South Africa.

When will Aspen's generic semaglutide be available in South Africa?

Aspen said commercialisation was expected to begin in Canada, Brazil and South Africa over the next few months. According to Business Insider Africa, the company has not given specific launch dates for any of the three countries.

How much will Aspen's generic semaglutide cost?

Aspen has not disclosed a price. Business Day reported that chief financial officer Sean Capazario said only that pricing would be below that of Novo Nordisk's Ozempic and Wegovy, without giving further details of the company's pricing strategy.

What is Aspen's generic semaglutide approved for?

According to Business Day, it is registered for treating adults with type 2 diabetes. Business Insider Africa described the approval as covering use with diet and exercise to improve blood-sugar control. Business Day reported that doctors may prescribe it off label for weight management.

Will Aspen's product be called Ozempic?

No. Business Insider Africa reported that the approvals do not allow Aspen to use the Ozempic or Wegovy names, which remain Novo Nordisk trademarks. Aspen has not yet announced the commercial name for its product in South Africa or Brazil.

Where will Aspen's generic semaglutide be made?

Business Day reported that it will initially be manufactured in India, with production later moving to Aspen's sterile facilities in South Africa and France. Reuters reported that the active ingredient is sourced from third-party suppliers, including Dr Reddy's for Canada.